Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 1:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 17,766 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Population Clear all

Conditions: Gingivitis, Plaque, Dental
Interventions: Test, Control; Drug
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: HIV/AIDS, Gender, Behavior and Behavior Mechanisms
Interventions: PrEP Demonstration Project; Behavioral
Lead sponsor: Hektoen Institute for Medical Research; Other
Eligibility: 15 Years to 24 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cardiac Failure, Renal Failure, Kidney Failure
Interventions: Protocolized Diuretic Strategy; Drug
Lead sponsor: Kelly V. Liang, MD; Other
Eligibility: 21 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Interventions: Life completion and preparation, Attention Control; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Opioid Use, Opioid Use, Unspecified, Patient Empowerment, Total Knee Arthoplasty, Total Hip Arthroplasty
Interventions: Opioid destruction education; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 100 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Benign Prostatic Hyperplasia
Interventions: tadalafil, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 1,058 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Greenwood, Indiana

Conditions: Diabetic Foot Ulcers
Interventions: DSC127, placebo vehicle gel, Standard of Care gel, Aquasite; Drug
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 33
States / cities: Mesa, Arizona • Phoenix, Arizona • Castro Valley, California + 25 more

Conditions: Diabetes Mellitus Type 2
Interventions: aleglitazar, lisinopril, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Chula Vista, California • Omaha, Nebraska • Dallas, Texas + 1 more

Conditions: Pain
Interventions: Ibuprofen 300 mg Oral Tablet, Ibuprofen 200 mg Oral Tablet, Placebo of PR tablet, Placebo of IR tablet; Drug
Lead sponsor: Reckitt Benckiser Healthcare (UK) Limited; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Parkinson Disease, Freezing of Gait Symptoms in Parkinson Disease
Interventions: Experimental intervention, Active intervention; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Tempe, Arizona • Portland, Oregon

Conditions: Diabetes Mellitus, Type 2
Interventions: Glimepiride, Placebo, Linagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 16
States / cities: Chula Vista, California • Pembroke Pines, Florida • Decatur, Georgia + 11 more

Conditions: Schizophrenia
Interventions: Paliperidone palmitate 25 mg eq., Paliperidone palmitate 150 mg eq., Placebo, Paliperidone palmitate 100 mg eq.; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 652 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 32
States / cities: Anaheim, California • Cerritos, California • Escondido, California + 29 more

Conditions: Pancreatic Cancer, Venous Thromboembolism
Interventions: Dalteparin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: PTSD, Obesity
Interventions: HARPP, control arm for HARPP trial; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Aging
Interventions: STEM; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 60 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Rhinitis, Allergic, Seasonal
Interventions: Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 12 Years and older
Enrollment: 727 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more

Conditions: Cardiac Arrest
Interventions: Active Remote Ischemic Conditioning, Sham Remote Ischemic Conditioning; Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer, Colorectal Cancer
Interventions: Telephone-Based exercise intervention; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2026
U.S. locations: 9
States / cities: La Jolla, California • San Francisco, California • Boston, Massachusetts + 6 more

Conditions: Gastric Cancer, Gastric Adenocarcinoma
Interventions: Rivoceranib, Placebo; Drug
Lead sponsor: Elevar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Scottsdale, Arizona • Rogers, Arkansas • Detroit, Michigan + 2 more

Conditions: Multiple System Atrophy
Interventions: TEV-56286, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 19
States / cities: La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more

Conditions: Obesity
Interventions: Mindful eating and movement; Behavioral
Lead sponsor: Northeastern University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Arthritis
Interventions: 12-weeks EnhanceFitness, Control; Behavioral
Lead sponsor: Jennifer Hootman; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Hematopoietic Stem Cell Transplant, Hematologic Malignancy
Interventions: Influenza vaccine; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 6 Months and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Breast Cancer, Cervical Cancer
Interventions: CLS Intervention, No CLS intervention; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 21 Years and older · Female only
Enrollment: 1,025 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Gingivitis Reduction After Use of 0.45% Stannous Fluoride Toothpaste

Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - Demonstration Project

Protocolized Diuretic Strategy in Cardiorenal Failure

Outlook Quality of Life Intervention

Patient Utilization of Opioid Destruction Bags in the Post-op Period

Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers

A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril

Efficacy of 300 mg Ibuprofen Prolonged-Release Tablets for the Treatment of Pain After Surgical Removal of Impacted Third Molars

TURN-IT FOG: Improving Turning and Freezing of Gait in People With PD

Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

Theory-Driven Manualized Approach to Improving New Learning and Memory in Healthy Aging and MCI

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Remote Ischemic Conditioning to Enhance Resuscitation (RICE) Pilot

The Active After Cancer Trial (AACT)

A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

The Mind-Body Project

Help Arthritis With Exercise in West Virginia

Influenza Vaccine Post Allogeneic Transplant

Using a Lay Health Worker Program to Increase Breast and Cervical Cancer Screening in Low-Income Hispanic Women